How automation can help biotech startups

The 21st century is quickly emerging as the Century of Biology, with discoveries happening at a rate that was previously unthinkable. Cutting-edge discoveries in this field have paved the way for real-world applications in fields from environmental conservation to personalized medicine.

This revolution was sparked by technologies like CRISPR-Cas9 and next-generation sequencing, but the integration of artificial intelligence and a variety of high throughput techniques is expected to accelerate development.

Scientists from both small and large firms are racing to use new scientific discoveries. With this pressure set to increase, successful innovators looking to make a real impact will need more than just a great idea; they will also need to embrace new technologies early on to develop and bring their vision to market effectively.

biotechImage Credit: PopTika /

A company can improve its trajectory by carefully addressing future needs: forward-thinking technology adoption early in its life cycle could pave the way to sustained funding and, eventually, commercialization ahead of competition.

For early-stage biotech companies, securing the next round of funding is not just a milestone; it often serves as a gateway to a new phase of research or growth. Each round of funding marks the beginning of a new countdown, accompanied by a fresh set of objectives. While this might seem like a race, the truth is that quality and the capacity to showcase readiness for the next phase are just as crucial as hitting predefined milestones.

Therefore, companies must not only move quickly before funding runs out or a competitor outpaces them but must do so in a credible and reproducible way to ensure investors have the confidence to finance their future growth.


Biotechnology startups encounter unique and difficult challenges throughout their existence. While it may seem that generating scientific outcomes within tight deadlines is paramount for survival, seasoned entrepreneurs understand that this simplistic view can be misleading. Meeting milestones alone does not guarantee additional funding, often leaving companies puzzled and uncertain about their future.

As investors are faced with a seemingly endless menu of companies, it becomes essential for those companies to proactively demonstrate that they are more than their recent scientific results. By demonstrating not only speed but scientific rigor, efficiency, and preparedness for the future, startup companies can distinguish themselves from the crowd, positioning themselves for success.

Last updated: Mar 29, 2024 at 12:38 PM


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Opentrons. (2024, March 29). How automation can help biotech startups. News-Medical. Retrieved on April 24, 2024 from

  • MLA

    Opentrons. "How automation can help biotech startups". News-Medical. 24 April 2024. <>.

  • Chicago

    Opentrons. "How automation can help biotech startups". News-Medical. (accessed April 24, 2024).

  • Harvard

    Opentrons. 2024. How automation can help biotech startups. News-Medical, viewed 24 April 2024,

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.